Fasting for 5 Days a Month Could Help Control Crohn's Disease Symptoms—Here's What the Research Shows

A new Stanford Medicine study shows that a short-term, calorie-restrictive diet significantly improved both symptoms and biological markers of inflammation in people with mild-to-moderate Crohn's disease. The findings, published in Nature Medicine in January 2026, offer patients and doctors a concrete dietary option for managing this chronic autoimmune condition that affects about a million Americans.

What Is This Fasting Diet, and How Does It Work?

The study tested what researchers call a "fasting mimicking diet" (FMD)—a plant-based, calorie-restrictive eating pattern that participants followed for five consecutive days each month. During those five days, participants consumed between 700 and 1,100 calories daily, with meals provided by the research team. For the remaining 25 days of each month, they ate their normal diet without restrictions.

The approach is designed to trigger metabolic changes similar to fasting while still providing nutrition. "We were very pleasantly surprised that the majority of patients seemed to benefit from this diet," said Dr. Sidhartha R. Sinha, an assistant professor of gastroenterology and hepatology at Stanford and senior author of the study. "We noticed that even after just one FMD cycle, there were clinical benefits".

How Many Patients Saw Improvement?

The study enrolled 97 participants across the United States, with 65 assigned to the fasting mimicking group and 32 in a control group that continued eating their normal diet. About two-thirds of the fasting mimicking group—roughly 67%—experienced improvement in their Crohn's symptoms. In comparison, less than half of the control group saw improvements, which researchers attributed to natural symptom fluctuations and continued standard care medications.

The improvements appeared relatively quickly. Some participants reported clinical benefits after completing just one cycle of the diet, suggesting that the effects don't require months of commitment to become noticeable.

What Happened to Inflammation Markers?

Beyond symptom relief, the researchers measured objective biological changes in blood and stool samples. They found a significant decline in fecal calprotectin—a protein in stool that indicates gut inflammation—in the fasting mimicking group compared with the control group. The team also observed reductions in inflammation-promoting lipid mediators (fatty acid derivatives) and found that immune cells from fasting mimicking diet participants produced fewer inflammatory molecules overall.

These biological improvements matter because they suggest the diet is actually reducing intestinal inflammation, not just masking symptoms. "Our goal in collecting these biospecimens was to dig deeper into why there's this differential response," Dr. Sinha explained. "Can we find mechanisms to explain the findings and signatures that might help predict patients who will respond to the diet?".

Steps to Understanding If This Diet Might Work for You

• Symptom Severity: The fasting mimicking diet was tested in people with mild-to-moderate Crohn's disease, not severe cases. If your symptoms are severe, discuss with your gastroenterologist whether this approach is appropriate for your situation.
• Medical Supervision: Participate in the diet under medical guidance, not on your own. Your doctor can monitor your nutritional status and adjust medications if needed, since the diet may change how your body responds to treatment.
• Realistic Expectations: About two-thirds of participants improved, meaning roughly one-third did not see significant benefits. The diet is not a cure and works best as part of a comprehensive treatment plan that may include medications.
• Side Effect Tolerance: Some participants experienced fatigue and headaches during the fasting days, though no serious side effects were reported. Plan to rest during your five-day fasting period if possible.

Why Doctors Have Struggled to Give Diet Advice for Crohn's Disease

Crohn's disease causes inflammation in the digestive tract, leading to symptoms like diarrhea, cramping, abdominal pain, and weight loss. Currently, steroids are the only approved medication specifically for mild Crohn's disease, but their long-term use carries significant side effects. This has left patients asking their doctors the most common question: "What should I eat?".

Until now, there have been few large, rigorous studies of dietary interventions for inflammatory bowel disease (IBD), the category that includes both Crohn's disease and ulcerative colitis. Dietary studies are notoriously difficult to conduct because participants' reports of what they eat aren't always accurate, and the placebo effect cannot be avoided when people know which diet they're following. This Stanford study overcame those challenges by measuring objective biological markers alongside symptom reports.

What's Next for This Research?

Researchers are now exploring whether changes in the gut microbiome—the community of bacteria living in your digestive tract—may help explain some of the benefits of the fasting mimicking diet. "There's still a lot more to be done to understand the biology behind how this and other diets work in patients with Crohn's disease," Dr. Sinha noted.

Meanwhile, major medical centers including UCSF and UC San Diego are conducting multiple clinical trials testing new medications for Crohn's disease, including drugs like mirikizumab, risankizumab, and upadacitinib in both pediatric and adult patients. These trials offer additional treatment options for people whose symptoms don't respond to current therapies.

For now, the Stanford findings provide physicians with evidence-based dietary guidance they can offer patients—something that has been lacking in Crohn's disease management. If you have mild-to-moderate Crohn's disease and are interested in trying the fasting mimicking diet, talk with your gastroenterologist about whether it's appropriate for your specific situation and how to implement it safely alongside your current treatment plan.